OSR (NASDAQ:OSRH) Shares Climb 1.3% – Still a Buy?

OSR Holdings, Inc. (NASDAQ:OSRH)’s stock price rose 1.3% during mid-day trading on Tuesday. The company traded as high as $0.2350 and last traded at $0.2076. Approximately 232,501 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 6,002,917 shares. The stock had previously closed at $0.2050.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, OSR has a consensus rating of “Sell”.

OSR Trading Up 1.3%

The stock has a market cap of $7.29 million, a price-to-earnings ratio of -0.56 and a beta of 0.49. The stock has a fifty day simple moving average of $0.31 and a 200-day simple moving average of $0.41.

OSR (NASDAQ:OSRH) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.02) EPS for the quarter. OSR had a negative return on equity of 8.36% and a negative net margin of 593.15%.The business had revenue of $0.32 million for the quarter.

Institutional Trading of OSR

An institutional investor recently bought a new position in OSR stock. Citadel Advisors LLC acquired a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 127,810 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned 0.36% of OSR as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 55.30% of the company’s stock.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.